Fig. 3From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysisORR analysis for NIVO3/IPI1. Figure shows ORR analysis for selected trial in which was administered NIVO3/IPI1 schedule. Fixed effect model—Heterogeneity not significant (P = 0.48). NIVO3/IPI1: nivolumab 3 mg/kg and ipilimumab 1 mg/kgBack to article page